Match the following clinical trial methodologies or drug advertisement strategies with their corresponding epidemiological implications or potential biases.
- Modified Intention-to-Treat (mITT) analysis that excludes randomized participants who did not receive at least one dose of the study drug.May disrupt the baseline prognostic balance achieved by randomization, potentially introducing selection bias.
- Highlighting a statistically significant composite endpoint where the benefit is driven solely by a reduction in mild events, with no difference in overall mortality.Uses more frequent, less critical events to power the study, which can mislead clinicians regarding the drug's impact on severe outcomes.
- Implementing an active-drug run-in phase prior to randomization and excluding individuals who develop early adverse effects.Compromises external validity by artificially enhancing the drug's safety and tolerability profile in the analyzed population.
- Promoting a 50% risk reduction in a marketing brochure when the target event rate decreased from 2 in 1000 to 1 in 1000.Magnifies the perceived clinical benefit by relying on relative metrics rather than absolute differences for rare outcomes.
Cevap
Modified ITT pairs with selection bias risk; Composite endpoints pair with misleading impact on severe outcomes; Active run-in phases pair with compromised external validity; Relative metrics pair with magnified perceived benefit.
Each methodological strategy corresponds directly to a specific epidemiological consequence. Accurately matching these concepts demonstrates the ability to critically evaluate the validity, safety, and clinical applicability of clinical trial data and promotional materials.
Adım Adım Çözüm
Anahtar Kavram
Critical appraisal of medical literature requires recognizing how study design choices (like mITT, run-in phases, composite endpoints) and data presentation (RRR vs. ARR) can bias results or mislead clinical interpretation.
Tahmini Süre:2m 0s